Drugs / Treg-enriched donor cell
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04678401 | Jan 2021 → Aug 2028 expected | acute myeloid leukemia, graft versus host disease, myelodysplastic syndrome | Dana-Farber Cancer Institute | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Treg-enriched donor cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04678401 ↗ |
| Modality | Cell therapy | “Treg-enriched donor cell” NCT04678401 ↗ |
| Route | Intravenous | “Cells will be given intravenously” NCT04678401 ↗ |